This review provides insight into the role of CD133 signaling in the PI3K/mTOR pathway which can lead to melanoma progression, drug resistance, and recurrence, and the impact of the CD133/PI3K/AKT/mTOR pathway as a therapeutic target for melanoma treatment. Here, PROM1 is linked to melanoma.